AU2016375338B2 - Zika virus vaccine - Google Patents

Zika virus vaccine Download PDF

Info

Publication number
AU2016375338B2
AU2016375338B2 AU2016375338A AU2016375338A AU2016375338B2 AU 2016375338 B2 AU2016375338 B2 AU 2016375338B2 AU 2016375338 A AU2016375338 A AU 2016375338A AU 2016375338 A AU2016375338 A AU 2016375338A AU 2016375338 B2 AU2016375338 B2 AU 2016375338B2
Authority
AU
Australia
Prior art keywords
zika virus
virus
seq
vaccine
zika
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016375338A
Other languages
English (en)
Other versions
AU2016375338A1 (en
Inventor
Jana BARBERO CALZADO
Mario NEBENFÜHR
Robert Schlegl
Michael Weber
Jürgen WRUSS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Valneva Austria GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57821924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016375338(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria GmbH filed Critical Valneva Austria GmbH
Publication of AU2016375338A1 publication Critical patent/AU2016375338A1/en
Application granted granted Critical
Publication of AU2016375338B2 publication Critical patent/AU2016375338B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016375338A 2015-12-23 2016-12-23 Zika virus vaccine Active AU2016375338B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP15202585.4 2015-12-23
EP15202585 2015-12-23
EP16161068.8 2016-03-18
EP16161068 2016-03-18
EP16176025 2016-06-23
EP16176049 2016-06-23
EP16176025.1 2016-06-23
EP16176049.1 2016-06-23
EP16182845.4 2016-08-04
EP16182845 2016-08-04
PCT/EP2016/082664 WO2017109225A1 (en) 2015-12-23 2016-12-23 Zika virus vaccine

Publications (2)

Publication Number Publication Date
AU2016375338A1 AU2016375338A1 (en) 2018-07-05
AU2016375338B2 true AU2016375338B2 (en) 2021-11-04

Family

ID=57821924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016375338A Active AU2016375338B2 (en) 2015-12-23 2016-12-23 Zika virus vaccine

Country Status (19)

Country Link
US (14) US11331382B2 (enExample)
EP (9) EP3393508B9 (enExample)
JP (1) JP6949027B2 (enExample)
KR (1) KR102950500B1 (enExample)
CN (2) CN108697785B (enExample)
AU (1) AU2016375338B2 (enExample)
BR (1) BR112018012873A2 (enExample)
CA (1) CA3009278A1 (enExample)
DK (1) DK3393510T4 (enExample)
ES (4) ES2950887T3 (enExample)
FI (1) FI3393510T4 (enExample)
HR (1) HRP20230273T1 (enExample)
HU (1) HUE061679T2 (enExample)
LT (1) LT3393510T (enExample)
MX (1) MX2018007627A (enExample)
PL (1) PL3393510T3 (enExample)
SG (1) SG11201805120YA (enExample)
SI (1) SI3393510T1 (enExample)
WO (6) WO2017109224A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
CA2992531C (en) * 2015-07-16 2023-09-26 Bharat Biotech International Limited Vaccine compositions
ES2950887T3 (es) 2015-12-23 2023-10-16 Valneva Austria Gmbh Purificación del Virus Zika
WO2018009604A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
CN118662621A (zh) 2017-09-21 2024-09-20 瓦尔尼瓦公司 包含免疫原性屈公病毒chikv-delta5nsp3的医药组成物的制备方法
MY202505A (en) * 2017-11-03 2024-05-01 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
CN107988239B (zh) * 2017-11-29 2021-03-19 南方医科大学 一种寨卡病毒的重组基因及其制备方法和应用
SG11202003975WA (en) 2017-11-30 2020-06-29 Takeda Vaccines Inc Method for inactivating zika virus and related methods
CN107904215B (zh) * 2017-12-27 2021-07-27 华农（肇庆）生物产业技术研究院有限公司 一种禽流感病毒的全悬浮培养方法
CN110156880B (zh) * 2018-02-13 2022-12-16 吴夙钦 兹卡病毒疫苗组合物及其应用
TWI658848B (zh) * 2018-02-13 2019-05-11 National Tsing Hua University 茲卡病毒疫苗組合物及其應用
CN119488586A (zh) 2018-03-26 2025-02-21 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
CN108676780B (zh) * 2018-07-24 2021-08-10 华中农业大学 一种高效分离猪肠道冠状病毒的方法
CN109337876A (zh) * 2018-10-15 2019-02-15 北京世纪元亨动物防疫技术有限公司 一种猪流行性腹泻病毒的纯化方法
JP7463366B2 (ja) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
CN109627297B (zh) * 2018-12-29 2022-06-14 复旦大学 来自寨卡病毒e蛋白的中和表位及其应用
AU2020211990A1 (en) * 2019-01-22 2021-08-12 2Seventy Bio, Inc. Methods and systems for manufacturing viral vectors
AU2020269164B2 (en) * 2019-05-08 2024-04-04 Takeda Vaccines, Inc. Inactivated virus compositions and Zika vaccine formulations
WO2021028406A1 (en) 2019-08-09 2021-02-18 Valneva Se Chikungunya vaccine formulations
CA3149932A1 (en) 2019-08-09 2021-02-18 Valneva Se Single shot chikungunya virus vaccine
EP4028511A1 (en) 2019-09-09 2022-07-20 Valneva Austria GmbH Inactivation process for viruses
KR102243295B1 (ko) * 2019-11-15 2021-04-23 강원대학교산학협력단 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
US12521429B2 (en) 2020-02-05 2026-01-13 New York Blood Center, Inc. Zika virus immunogenic compositions
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
JP2023515908A (ja) 2020-03-01 2023-04-14 ヴァルネヴァ・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ＣｐＧアジュバント化ＳＡＲＳ－ＣｏＶ－２ウイルスワクチン
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
CA3173301A1 (en) * 2020-03-03 2021-09-10 Mayo Foundation For Medical Education And Research Zika virus polypeptides
WO2021178877A1 (en) 2020-03-06 2021-09-10 The Colorado State University Research Foundation Production of vaccines comprising inactivated sars-cov-2 viral particles
PY2126530A (es) 2020-04-06 2022-09-12 Valneva Austria Gmbh VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
JP2023527169A (ja) 2020-05-20 2023-06-27 タケダ ワクチン，インコーポレイテッド 抗原の効力を決定するための方法
US20230324404A1 (en) 2020-05-20 2023-10-12 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
US20250381261A1 (en) * 2022-02-09 2025-12-18 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2025099278A2 (en) * 2023-11-08 2025-05-15 Valneva Austria Gmbh Immunogenic zika virus compositions and uses thereof
WO2026052881A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Chikungunya virus vaccine multidose formulation and use thereof in outbreaks
WO2026052882A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Yellow fever virus (yfv) compositions and production thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309650B1 (en) * 1997-08-28 2001-10-30 Cheil Jedang Corporation Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
WO2017009873A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86061A (en) * 1869-01-19 Improved horse-power
WO2000014245A1 (en) * 1998-09-02 2000-03-16 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Dengue viruses that are replication defective in mosquitos for use as vaccines
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
WO2002074963A1 (en) * 2001-03-16 2002-09-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Dengue viruses that are replication defective in mosquitos for use as vaccines
WO2002089840A1 (en) * 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
BRPI0716145B1 (pt) * 2006-09-01 2021-06-22 Bharat Biotech International Limited Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya
WO2009048633A2 (en) 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
WO2009129616A1 (en) * 2008-04-21 2009-10-29 Tissue Regeneration Therapeutics, Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
CN102317308A (zh) * 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
EP4400115A3 (en) 2011-12-06 2024-10-23 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
WO2016145149A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
ES2950887T3 (es) 2015-12-23 2023-10-16 Valneva Austria Gmbh Purificación del Virus Zika
CN105749268B (zh) * 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
CN118662621A (zh) 2017-09-21 2024-09-20 瓦尔尼瓦公司 包含免疫原性屈公病毒chikv-delta5nsp3的医药组成物的制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309650B1 (en) * 1997-08-28 2001-10-30 Cheil Jedang Corporation Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
WO2017009873A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SRIVASTAVA A K ET AL, "A purified inactivated Japanese encephalitis virus vaccine made in vero cells", VACCINE, vol. 19, no. 31, ISSN 0264-410X, (2001-08-14), pages 4557 - 4565, (2001-08-14) *

Also Published As

Publication number Publication date
EP3393506B1 (en) 2024-03-13
LT3393510T (lt) 2023-03-27
SI3393510T1 (sl) 2023-04-28
EP4357355A3 (en) 2024-09-25
US11331382B2 (en) 2022-05-17
EP3393508B1 (en) 2023-06-07
WO2017109229A1 (en) 2017-06-29
EP4393938A2 (en) 2024-07-03
DK3393510T5 (da) 2024-09-30
EP3393509B1 (en) 2024-02-28
EP3393507C0 (en) 2024-02-07
ES2950887T3 (es) 2023-10-16
US20200197506A1 (en) 2020-06-25
US11951163B2 (en) 2024-04-09
PL3393510T3 (pl) 2023-06-26
US11406700B2 (en) 2022-08-09
US10660950B2 (en) 2020-05-26
US10537630B2 (en) 2020-01-21
KR20180097558A (ko) 2018-08-31
JP6949027B2 (ja) 2021-10-20
EP4218807A3 (en) 2023-09-06
AU2016375338A1 (en) 2018-07-05
EP3393506C0 (en) 2024-03-13
ES2973267T3 (es) 2024-06-19
US11207397B2 (en) 2021-12-28
US20200368342A1 (en) 2020-11-26
US12102673B2 (en) 2024-10-01
EP3393510B1 (en) 2023-02-22
JP2019504030A (ja) 2019-02-14
US20210093707A1 (en) 2021-04-01
DK3393510T4 (da) 2026-07-27
HRP20230273T1 (hr) 2023-04-28
EP4253403A2 (en) 2023-10-04
US11219681B2 (en) 2022-01-11
US10744194B2 (en) 2020-08-18
US11524064B2 (en) 2022-12-13
DK3393510T3 (da) 2023-03-13
WO2017109223A1 (en) 2017-06-29
MX2018007627A (es) 2019-02-14
US20180362936A1 (en) 2018-12-20
SG11201805120YA (en) 2018-07-30
US20200017555A9 (en) 2020-01-16
ES2976311T3 (es) 2024-07-29
FI3393510T4 (fi) 2026-07-15
EP3393508C0 (en) 2023-06-07
CN108697785A (zh) 2018-10-23
EP3393507B1 (en) 2024-02-07
EP4253403A3 (en) 2023-12-27
EP3393508A1 (en) 2018-10-31
FI3393510T3 (fi) 2023-03-22
EP3393509A1 (en) 2018-10-31
US20250018023A1 (en) 2025-01-16
US20200384099A1 (en) 2020-12-10
WO2017109224A1 (en) 2017-06-29
US20180371027A1 (en) 2018-12-27
CA3009278A1 (en) 2017-06-29
US12214033B2 (en) 2025-02-04
US20190008945A1 (en) 2019-01-10
WO2017109225A1 (en) 2017-06-29
US12005111B2 (en) 2024-06-11
US20180369359A1 (en) 2018-12-27
CN115381934A (zh) 2022-11-25
US20230056142A1 (en) 2023-02-23
US20230226165A1 (en) 2023-07-20
KR102950500B1 (ko) 2026-04-08
ES2941967T3 (es) 2023-05-29
HUE061679T2 (hu) 2023-08-28
BR112018012873A2 (pt) 2018-12-04
US20240108712A1 (en) 2024-04-04
EP4218807A2 (en) 2023-08-02
EP3393508B9 (en) 2023-09-27
US20220273786A1 (en) 2022-09-01
WO2017109227A1 (en) 2017-06-29
EP3393509C0 (en) 2024-02-28
EP3393507A1 (en) 2018-10-31
US20180362937A1 (en) 2018-12-20
US10639365B2 (en) 2020-05-05
EP4393938A3 (en) 2024-08-07
WO2017109228A1 (en) 2017-06-29
CN108697785B (zh) 2022-08-02
EP3393510A1 (en) 2018-10-31
EP4357355A2 (en) 2024-04-24
EP3393506A1 (en) 2018-10-31
EP3393510B2 (en) 2026-06-24

Similar Documents

Publication Publication Date Title
KR102950500B1 (ko) 지카 바이러스 백신
KR20170102905A (ko) 신규 다가 나노입자 기반 백신
CN112575008A (zh) 编码新型冠状病毒的结构蛋白的核酸分子以及新型冠状病毒疫苗
CN110734500A (zh) 用于登革病毒疫苗的方法与组合物
CN115666633A (zh) CpG-佐剂的SARS-CoV-2病毒疫苗
HK40077936A (en) Zika virus vaccine
HK1261387A1 (en) Zika virus vaccine
HK1261387B (en) Zika virus vaccine
EP3826672A1 (en) Zika virus vaccine
HK40098392A (en) Zika virus vaccine
HK40103263A (en) Virus purification
HK1261325A1 (en) Zika virus purification
HK1261325B (en) Zika virus purification
HK1261388A1 (en) Zika virus vaccine
HK1261388B (en) Zika virus vaccine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)